Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 0,39 € (-95,49 %). La mediana es de 0,39 € (-95,49 %).
| Comprar |
0 |
| Mantener |
2 |
| Vender |
0 |
Noticias Ir al feed de noticias
Vireo Growth acquires C21 Investments, expands Nevada presence
Vireo Growth has completed the acquisition of C21 Investments through a court‑approved arrangement proceeding and issued 2,766,409 Vireo shares in connection with the deal. C21 shareholders received 0.023052 subordinate voting Vireo shares for each common share; C21’s shares are to be delisted from the CSE and OTCQX trading will be discontinued. The acquisition gives Vireo three additional retail locations in Nevada and roughly 104,000 square feet of cultivation and production capacity, bringing its Nevada footprint to about 14 retail locations and 159,000 square feet of capacity. » Más en de.investing.com
Vireo Growth acquires PhytoNatural and secures Pennsylvania license for up to six dispensaries
Vireo Growth has completed the acquisition of PhytoNatural, thereby obtaining a previously unused license to distribute medical cannabis in Pennsylvania. The transaction was carried out through the joint venture Vive Penn with Hive Holdings and has a total value of $20.0 million, consisting of $8.0 million in cash and roughly $12.0 million in approximately 645,161 subordinated voting shares to be issued in two years. The license permits, subject to regulatory approvals, the operation of up to six dispensing locations; Vireo already operates more than 170 dispensaries across ten U.S. states. » Más en de.investing.com
Vireo Growth completes acquisition of Bridgewell for $13.66 million
Vireo Growth has completed the acquisition of Agribusiness Holdings Limited Partnership, including Bridgewell; the final purchase price for the Bridgewell transaction is approximately $13.66 million. As consideration, the sellers were issued unsecured, subordinated convertible notes that are convertible, at the earliest in two years, into an estimated 22,036,528 subordinated voting shares at an assumed price of $0.62 per share (pre-consolidation). Vireo cites strong revenue growth (251% to $350.47 million) and also reports the purchase of the M3 Wellness dispensary in Nevada for $500,000 as well as a previously agreed 49% stake in two Maryland companies for $1.55 million, both transactions subject to regulatory approvals. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 183,39 M | 349,73 % |
| Beneficio bruto | 83,5 M | 382,04 % |
| Beneficio neto | -85,4 mil | 99,33 % |
| EBITDA | 16,65 M | 4261,36 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 348,54 M € |
Número de acciones | 38,25 M |
Máximo/mínimo de 52 semanas | 19,43 € - 7,70 € |
| Dividendos | No |
Beta | 0,07 |
Ratio P/E | -5,34 |
Ratio PEG | -0,08 |
Ratio P/B | 1,07 |
Ratio P/S | 0,79 |
Perfil de la empresa
| Nombre | Vireo Growth Aktie |
| CEO | John Mazarakis |
| Empleados | 612 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
München | 0ZF.MU |
Descubrir activos
Los accionistas de Vireo Growth Aktie también invierten en los siguientes activos






